Cardium Therapeutics, Inc. Form 8-K February 19, 2009

## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

## **CURRENT REPORT**

pursuant to Section 13 or 15(d)

### of the Securities Exchange Act of 1934

DATE OF REPORT (Date of earliest event reported): February 19, 2009

001-33635

(Commission file number)

# **CARDIUM THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

Delaware (State of incorporation) 27-0075787 (IRS Employer Identification No.)

12255 El Camino Real, Suite 250 San Diego, California 92130 (Address of principal executive offices)

(858) 436-1000 (Registrant s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

" Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

## Edgar Filing: Cardium Therapeutics, Inc. - Form 8-K

- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### ITEM 8.01 OTHER EVENTS.

On February 19, 2009, Cardium Therapeutics, Inc. (Cardium) issued a press release announcing that its exchange listing compliance plan submitted on January 23, 2009 has been accepted by the NYSE Alternext US LLC (formerly the American Stock Exchange). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

#### ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

- (d) Exhibits.
- 99.1 Press Release of Cardium issued on February 19, 2009.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### CARDIUM THERAPEUTICS, INC.

Date: February 19, 2009

By: /s/ Christopher J. Reinhard Christopher J. Reinhard Chief Executive Officer